Skip to main content

Table 1 Patient demographics, tumor histology, and laboratory results

From: Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study

 

RR-DTC

Non-RR-DTC

P-value

223

181

Sex (male/female)

70/153

50/131

0.410

Age (mean ± SD, years)

48.79 ± 13.93

43.49 ± 11.88

0.001*

 ≥ 48/ < 48

129/94

67/114

0.001*

Operation frequency (once/two or more)

162/61

159/22

0.001*

Histological subtype (PTC/FTC/Mixed)

208/6/8

179/2/0

0.722

Recurrence risk group (low, medium/high risk)

26/197

24/157

0.627

Extrathyroidal extension (no/pathological/intraoperative/both)

117/39/40/27

113/28/26/14

0.203

Autoimmune thyroid disease (no/yes)

187/36

133/48

0.011*

Tumor diameter (mean ± SD, mm)

2.08 ± 1.58

1.68 ± 1.26

0.007*

 ≥ 18.5/ < 18.5

114/109

57/124

0.001*

Multi-focality (no/yes)

95/128

79/102

0.833

Site of lymph node metastasis (no/central/lateral neck region/both)

22/42/23/136

13/49/16/103

0.230

Numbers of lymph node metastasis (mean ± SD, number)

9.20 ± 8.16

9.02 ± 8.33

0.832

Proportion of lymph node metastasis (mean ± SD, %)

37.07 ± 0.27

40.05 ± 0.27

0.265

Locally advanced (no/yes)

190/33

164/17

0.103

Clinical stage (I/II/III/IVA/IVB)

110/63/7/0/43

135/31/10/2/3

0.001*

Recurrence between the operation and iodine-131 treatment (no/yes)

167/56

161/20

0.001*

Time from the first operation to the first iodine-131 treatment (mean ± SD, months)

25.93 ± 56.64

8.90 ± 22.66

0.001*

 ≥ 16/ < 16

52/171

16/165

0.001*

Site of metastasis

   

(single-site/multi-partial metastases)

143/80

170/11

0.001*

(local/distant metastases)

133/90

155/26

0.001*

Uptake of 131I (negative/positive)

123/100

92/89

0.386

Uptake of 18F-FDG (negative/positive)

61/162

170/11

0.001*

  1. *Statistically significant difference
  2. RR-DTC, radioiodine refractory differentiated thyroid carcinoma; SD, standard deviation; 18F-FDG, 18F-fluorodeoxyglucose; PTC, papillary thyroid carcinoma; FTC, follicular thyroid cancer